Claims
- 1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula:
- 2. The pharmaceutical composition of claim 1 wherein X is a covalent bond, —C(R4R5)-, —N(R4)-, —O—, C(═O)—, —C(═O)—N(R4)- or —N(R4)—C(═O)— and R3 is a substituted or unsubstituted aryl group.
- 3. The pharmaceutical composition of claim 2 wherein R is represented by a structural formula selected from:
- 4. The pharmaceutical composition of claim 3 wherein Rings A-F are a substituted or unsubstituted phenyl group; R2 is —H; Z1 is ═O; and X is —C(R4R5)-, —N(R4)- or —O—.
- 5. The pharmaceutical composition of claim 4 wherein X is —C(R4R5)-.
- 6. The pharmaceutical composition of claim 5 wherein R1 is represented by the following structural formula:
- 7. The pharmaceutical composition of claim 6 wherein:
R6 is —H, C1—C4 alkyl, C1—C4 hydroxyalkyl, —(C1—C4 alkylene)-O—(C1—C4 alkylene)-tri(C1—C4 alkyl)silane, —S(O)2N(C1—C4 alkyl)2, —S(O)2NH(C1—C4 alkyl) or —S(O)2NH2; R7 and R8 are independently —H, C1—C4 alkyl, C1—C4 hydroxylalkyl, (C1—C4 alkyl)3-Si—O—(C1—C4 alkylene), pyridyl, C1—C4 alkyl substituted with pyridyl, C1—C4 alkyl substituted with —NH-pyridyl, C1—C4 hydroxyalkyl substituted with —NH-pyridyl, C1—C4 hydroxyalkyl substituted with -pyridyl, —S(O)2-(phenyl), —S(O)2-(tolulyl), 91 —C(O)-pyridyl, indolyl, —(C1—C4 alkylene)-O—(C1—C4 alkyl), C1—C4 alkyl substituted with —O-pyridyl, —CHO, —C(O)—O—(C1—C4 alkyl), —C(O)—NH—(C1—C4 alkyl), —C(O)—(C1—C4 alkylene)-pyridyl, oxazolinyl, —C(O)—(C1—C4 alkyl), —C═N—NH-phenyl, —C(O)—NH-pyridyl, —C(O)—NH-phenyl, —C═N—NH—(C1—C4 alkyl), —C═N—N—(C1—C4 alkyl)2, —C(O)—NH—(C1—C4 alkyl), —C(O)—N—(C1—C4 alkyl)2, —C(O)—(N-morphilino), —C(O)-imidazolyl, —C(O)—NH—(C1—C4 haloalkyl), —C(O)—N—(C1—C4 haloalkyl)2, —CH2—N3, C1—C4 alkyl substituted with imidazolyl, —C1—C4 alkylene-NHC(O)—(C1—C4 alkyl), —C1—C4 alkylene-NHC(O)-(phenyl), —(C1—C4 alkylene)-NHC(O)-(tolulyl), —C1—C4-alkylene-NHC(O)-(methoxy, dimethoxy or trimethoxyphenyl); and Y is —S—, —O— or —N(H or C1—C4 alkyl or substituted alkyl)-.
- 8. The pharmaceutical composition of claim 7 wherein R4 and R5 are both —H; and R3 is a substituted or unsubstituted phenyl or pyridyl group.
- 9. The pharmaceutical composition of claim 8 wherein Rings A and D are unsubstituted or substituted with one or more groups selected from —F, —Cl, —Br, —C1—C4 alkyl, C1—C4 alkoxy, —C1—C4 haloalkyl, C1—C4 haloalkoxy, —CN and —NH2.
- 10. The pharmaceutical composition of claim 9 wherein R is represented by the following structural formula:
- 11. The pharmaceutical composition of claim 10 wherein:
R3 is a phenyl or pyridyl group substituted with zero, one or more groups selected from —Br, —Cl, —F, -Re, —ORe, —CN, —COORe, —N(Re)2, —CON(Re)2, —NReCORf, —NHCONH2 and —SO2 N(Re)2; and each Re and Rf are independently selected from —H, alkyl, and substituted alkyl.
- 12. The pharmaceutical composition of claim 11 wherein R3 is a phenyl group substituted with zero, one or more groups selected from —Cl, —F, -Re, —ORe, —CN, —NH2, —CONH2, and —NHCORf.
- 13. The pharmaceutical composition of claim 12 wherein R3 is a phenyl group substituted with zero, one or more groups selected from —CH3, —CH2CH3, —F, —Cl, —CN and —OCH3.
- 14. The pharmaceutical composition of claim 13 wherein R3 is an unsubstituted phenyl group or a phenyl group monosubstituted with —CH3, —CH2CH3, —F, —Cl, —CN or —OCH3, wherein the phenyl group substituent is at the para position.
- 15. The pharmaceutical composition of claim 14 wherein R1 is represented by the following structural formula:
- 16. The pharmaceutical composition of claim 15 wherein Ring A is unsubstituted.
- 17. The pharmaceutical composition of claim 9 wherein R is represented by the following structural formula:
- 18. The pharmaceutical composition of claim 17 wherein:
R3 is a phenyl or pyridyl group substituted with zero, one or more groups selected from —Br, —Cl, —F, -Re,—ORe, —CN, —COORe, —N(Re)2, —CON(Re)2, —NReCORf, —NHCONH2 and —SO2 N(Re)2; and each Re and Rf is independently selected from —H, alkyl and substituted alkyl.
- 19. The pharmaceutical composition of claim 18 wherein R3 is a phenyl group substituted with zero, one or more groups selected from —Cl, —F, -Re, —ORe, —CN, —NH2, —CONH2 and —NHCORf.
- 20. The pharmaceutical composition of claim 19 wherein R3 is a phenyl group substituted with zero, one, or more groups selected from —CH3, —CH2CH3, —F, —Cl, —CN and —OCH3.
- 21. The pharmaceutical composition of claim 20 wherein R3 is an unsubstituted phenyl group or a phenyl group monosubstituted with —CH3, —CH2CH3, —F, —Cl, —CN or —OCH3, wherein the phenyl group substituent is at the para position.
- 22. The pharmaceutical composition of claim 21 wherein R1 is represented by the following structural formula:
- 23. The pharmaceutical composition of claim 22 wherein Ring D is unsubstituted.
- 24. The pharmaceutical composition of claim 1 wherein R1 is represented by the following structural formula:
- 25. A pharmaceutical composition represented by the following structural formula:
- 26. The pharmaceutical composition of claim 25 wherein X is —C(R4R5)-.
- 27. The pharmaceutical composition of claim 26 wherein X is —CH2— and Ring G is unsubstituted.
- 28. The pharmaceutical composition of claim 25 wherein:
Rings A and D are unsubstituted or substituted with one or more substituents selected from —F, —Cl, —Br, —C1—C4 alkyl, C1—C4 alkoxy, —C1—C4 haloalkyl, C1—C4 haloalkoxy, —CN and —NH2; R3 is a phenyl or pyridyl group substituted with zero, one or more groups selected from —Br, —Cl, —F, -Re, —ORe, —CN, —COORe, —N(Re)2, —CON(Re)2, —NReCORf, —NHCONH2 and —SO2 N(Re)2; and each Re and Rf is independently selected from —H, alkyl, and substituted alkyl.
- 29. The pharmaceutical composition of claim 28 wherein R3 is a phenyl group substituted with zero, one, or more groups selected from —Cl, —F, -Re, —ORe, —CN, —NH2, —CONH2, and —NHCORf.
- 30. The pharmaceutical composition of claim 29 wherein R3 is a phenyl group substituted with zero, one or more groups selected from —CH3, —CH2CH3, —OCH3, —CN, —F, and —Cl.
- 31. A pharmaceutical composition represented by the following structural formula:
- 32. A pharmaceutical composition represented by the following structural formula:
- 33. A pharmaceutical composition represented by the following structural formula:
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser. No. 10/233,371, filed Aug. 29, 2002, which claims the benefit of U.S. Provisional Application No. 60/322,105, filed on Sep. 13, 2001. The entire teachings of the above applications are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60322105 |
Sep 2001 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
10233371 |
Aug 2002 |
US |
Child |
10802292 |
Mar 2004 |
US |